Prazosin
- Atc Codes:C02CA01
- CAS Codes:19237-84-4#19216-56-9
- PHARMGKB ID:19237-84-4#19216-56-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Minipress; Belgium: Minipress; Bulgaria: Prazosin; Cyprus: Minipress; Czech Republic: Deprazolin; Finland: Pratsiol; France: Alpress, Minipress; Germany: Adversuten, Minipress, Prazosin; Greece: Minipress, Prestop; Hungary: Minipress; Ireland: Hypovase; Luxembourg: Minipress, Prazosin; Netherlands: Prazosine; Poland: Minipress, Polpressin; Romania: Minipress; Slovakia: Deprazolin; Slovenia: Vasoflex; Spain: Minipres; UK: Hypovase.
North America
Canada: Minipress, Prazin, Prazo; USA: Minipress, Prazosin.
Latin America
Brazil: Minipress; Mexico: Ensibest, Minipres, Sinozzard.
Asia
Japan: Coltock, Daldanon, Downat, Downpress, Enzosine, Isepress, Kachilet, Minipress, Mizpiron, Queenpress, Trabuzon.
Drug combinations
Chemistry
Prazosin Hydrochloride: C~19~H~21~N~5~O~4~ HCl. Mw: 419.86. (1) Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-, monohydrochloride; (2) 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazine monohydrochloride. CAS-19237-84-4; CAS-19216-56-9 (prazosin)(1968).
Pharmacologic Category
Cardiovascular Drugs; α-Adrenergic Blocking Agents. (ATC-Code: C02CA01).
Mechanism of action
Competitively inhibits postsynaptic α-adrenergic receptors which results in vasodilation of veins and arterioles and decrease in total peripheral resistance and blood pressure.
Therapeutic use
Treatment of hypertension.
Pregnancy and lactiation implications
Use with caution in pregnancy and lactation.
Unlabeled use
Post-traumatic stress disorder. Benign prostatic hyperplasia. Raynaud’s syndrome.
Contraindications
Hypersensitivity to quinazolines (doxazosin, prazosin, terazosin) or any component of the formulation. Concurrent use with PDE-5 inhibitors including sildenafil (>25 mg), tadalafil, or vardenafil.
Warnings and precautions
Symptoms of angina might occur or worsen. May cause significant orthostatic hypotension and syncope, especially with first dose. Prostate cancer should be ruled out before beginning therapy.